NPI: 1033264767 · NEWPORT NEWS, VA 23606 · Pediatrics Physician · NPI assigned 01/24/2007
Authorized official ABSHIRE, KATHRYN controls 20+ related entities in our dataset. Read more
| Authorized Official | ABSHIRE, KATHRYN (SENIOR VP/CFO) |
| Parent Organization | CHILDRENS MEDICAL GROUP INC |
| NPI Enumeration Date | 01/24/2007 |
Other providers sharing the same authorized official: ABSHIRE, KATHRYN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 17,271 | $576K |
| 2019 | 32,026 | $983K |
| 2020 | 33,954 | $1.05M |
| 2021 | 41,042 | $1.13M |
| 2022 | 39,626 | $1.13M |
| 2023 | 34,678 | $1.10M |
| 2024 | 33,813 | $1.13M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34,405 | 31,128 | $2.12M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 14,656 | 14,065 | $1.21M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 14,701 | 13,020 | $1.12M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8,544 | 8,239 | $695K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3,695 | 3,434 | $328K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6,456 | 5,972 | $228K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2,584 | 2,457 | $222K |
| 90670 | 8,387 | 7,730 | $137K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 13,794 | 9,250 | $124K |
| 90698 | 8,568 | 7,652 | $109K | |
| 90686 | 8,648 | 8,176 | $102K | |
| 90680 | 6,230 | 5,752 | $86K | |
| 87428 | 1,527 | 1,433 | $54K | |
| 92551 | 5,270 | 5,069 | $54K | |
| 90633 | 4,353 | 4,101 | $54K | |
| 90744 | 3,468 | 3,161 | $41K | |
| 90677 | 1,292 | 1,222 | $35K | |
| 96127 | 6,602 | 5,954 | $34K | |
| 96161 | 13,500 | 12,178 | $33K | |
| 99174 | 4,944 | 4,737 | $26K | |
| 90651 | 1,057 | 997 | $26K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 720 | 701 | $24K |
| 96160 | 11,007 | 8,659 | $23K | |
| 99381 | 304 | 250 | $23K | |
| 90671 | 1,109 | 1,047 | $22K | |
| 90697 | 1,153 | 1,098 | $21K | |
| 83655 | 1,770 | 1,701 | $21K | |
| 85018 | 7,543 | 7,178 | $19K | |
| 99173 | 5,004 | 4,799 | $13K | |
| 90710 | 556 | 527 | $13K | |
| 0071A | 268 | 253 | $11K | |
| 90685 | 836 | 730 | $9K | |
| 90656 | 484 | 478 | $9K | |
| 80061 | Lipid panel | 582 | 559 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 559 | 505 | $7K |
| 90696 | 490 | 465 | $7K | |
| 90707 | 460 | 432 | $6K | |
| 90716 | 446 | 409 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 418 | 196 | $6K |
| 0072A | 108 | 107 | $5K | |
| 90734 | 259 | 233 | $4K | |
| 99383 | 44 | 41 | $4K | |
| 90619 | 153 | 146 | $3K | |
| 1128F | 9,260 | 8,472 | $3K | |
| 36416 | 7,974 | 7,536 | $2K | |
| 90700 | 162 | 154 | $2K | |
| 90620 | 32 | 32 | $1K | |
| 94760 | 1,264 | 1,168 | $1K | |
| 0081A | 31 | 29 | $1K | |
| 1127F | 2,256 | 2,161 | $981.88 | |
| 99000 | 409 | 384 | $898.63 | |
| 90648 | 74 | 69 | $744.62 | |
| 81002 | 274 | 237 | $738.95 | |
| 99188 | 30 | 29 | $697.52 | |
| 91321 | 40 | 26 | $660.16 | |
| 90715 | 52 | 50 | $637.14 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 35 | 31 | $570.33 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 29 | 28 | $226.60 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 14 | 14 | $98.15 |
| 99051 | 122 | 116 | $59.20 | |
| 82962 | 16 | 14 | $25.27 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 48 | 43 | $5.33 |
| 91308 | 110 | 101 | $0.93 | |
| 91307 | 446 | 426 | $0.60 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 14 | 14 | $0.00 |
| G9920 | Screening performed and negative | 308 | 298 | $0.00 |
| 91300 | 76 | 74 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 2,380 | 2,143 | $0.00 |